Author: Noce, Annalisa; Albanese, Maria; Marrone, Giulia; Di Lauro, Manuela; Pietroboni Zaitseva, Anna; Palazzetti, Daniela; Guerriero, Cristina; Paolino, Agostino; Pizzenti, Giuseppa; Di Daniele, Francesca; Romani, Annalisa; D’Agostini, Cartesio; Magrini, Andrea; Mercuri, Nicola Biagio; Di Daniele, Nicola
Title: Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients Cord-id: k6wnm2qh Document date: 2021_4_6
ID: k6wnm2qh
Snippet: The Coronavirus Disease-19 (COVID-19) pandemic has caused more than 100,000,000 cases of coronavirus infection in the world in just a year, of which there were 2 million deaths. Its clinical picture is characterized by pulmonary involvement that culminates, in the most severe cases, in acute respiratory distress syndrome (ARDS). However, COVID-19 affects other organs and systems, including cardiovascular, urinary, gastrointestinal, and nervous systems. Currently, unique-drug therapy is not suppo
Document: The Coronavirus Disease-19 (COVID-19) pandemic has caused more than 100,000,000 cases of coronavirus infection in the world in just a year, of which there were 2 million deaths. Its clinical picture is characterized by pulmonary involvement that culminates, in the most severe cases, in acute respiratory distress syndrome (ARDS). However, COVID-19 affects other organs and systems, including cardiovascular, urinary, gastrointestinal, and nervous systems. Currently, unique-drug therapy is not supported by international guidelines. In this context, it is important to resort to adjuvant therapies in combination with traditional pharmacological treatments. Among natural bioactive compounds, palmitoylethanolamide (PEA) seems to have potentially beneficial effects. In fact, the Food and Drug Administration (FDA) authorized an ongoing clinical trial with ultramicronized (um)-PEA as an add-on therapy in the treatment of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. In support of this hypothesis, in vitro and in vivo studies have highlighted the immunomodulatory, anti-inflammatory, neuroprotective and pain-relieving effects of PEA, especially in its um form. The purpose of this review is to highlight the potential use of um-PEA as an adjuvant treatment in SARS-CoV-2 infection.
Search related documents:
Co phrase search for related documents- abdominal pain and action mechanism: 1
- abdominal pain and activate platelet: 1
- abdominal pain and activation inflammatory: 1
- abdominal pain and acute acute pancreatitis: 1, 2, 3, 4, 5, 6, 7, 8, 9
- abdominal pain and acute chronic: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- abdominal pain and acute pancreatitis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- abdominal pain and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- ace receptor and action mechanism: 1, 2, 3, 4, 5, 6, 7
- ace receptor and activation inflammatory: 1, 2, 3
- ace receptor and acute acute pancreatitis: 1
- ace receptor and acute chronic: 1, 2, 3, 4, 5, 6
- ace receptor and acute pancreatitis: 1, 2, 3
- ace receptor and acute release: 1
- ace receptor and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- ace receptor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- ace receptor and acute tubular damage: 1
- action mechanism and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- action mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date